Chiron Capital Management’s BioNTech BNTX Stock Holding History

Chiron Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100	Closed	-$7K	–	126
2020 Q3	$7K	Buy	+100	New	+$7.17K	0.01%	321

Other funds holding BNTX

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Chiron Capital Management's BNTX Position: Q4 2020 in Review

Chiron Capital Management sold out of BioNTech (BNTX) in Q4 2020, closing a stake of 100 shares — an estimated $7K sold.

Chiron Capital Management first reported a position in BNTX in Q3 2020 and held it in 1 quarter. The position peaked at $7K in Q3 2020. 194 funds tracked by Wall St. Rank hold BNTX as of Q4 2020.

Chiron Capital Management reported no remaining BioNTech position as of Q4 2020 after selling out during the quarter.
Chiron Capital Management sold 100 BioNTech shares in Q4 2020, an estimated $7K.
Chiron Capital Management first reported a position in BioNTech in Q3 2020 and held it in 1 quarter.
Chiron Capital Management's BioNTech position peaked at $7K in Q3 2020.
194 funds tracked by Wall St. Rank held BioNTech as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.